Cancer prevention and control is a worldwide problem. In recent years, the overall incidence and mortality of cancer in China have shown an upward trend year by year, and cancer has become a major public health problem that seriously threatens the health of Chinese residents. The high prevalence and mortality rate of cancer provide a huge market for the development of cancer treatment drugs. For these reasons, the research and development of anti-tumor drugs has always been the focus of innovative drug research and development, and the research heat continues to rise. However, the sudden increase in the number of drugs under development has not led to an increase in the number of drugs on the market, and the huge gap between the number of drugs under development and the number of drugs on the market also reflects the difficulty of anti-cancer drug development. These challenges are driving the search for ways to develop drugs that increase success rates, reduce time, and reduce costs.
New use of an old drug refers to the use of the drug for another indication other than the originally approved use. Large amounts of data are often available for the new use of old drugs, reducing the time and cost of pharmacokinetic studies and toxicity studies. With the development of bioinformatics and cheminformatics, big data analysis, platform screening and other methods have been applied to new uses of old drugs, and the discovery of new uses of old drugs has become more systematic and targeted. The signaling mechanism involved in the pathological process of tumor is very complex, whether it is growth signaling pathway, energy metabolism or immune regulation can affect the occurrence and development of tumors, so the probability of finding anti-tumor active drugs from old drugs is higher. The compound library is a collection of compounds with the same characteristics, and the purposeful screening of the compound library is the starting point for the new use of old drugs and a necessary prerequisite for subsequent research.
In order to integrate the data resources and results of hypoglycemic drugs and antithyroid hormone compounds in cancer and promote related research, a literature review and information extraction analysis were carried out, so as to construct a database of hypoglycemic and anti-thyroid agents to assist in early diagnosis and treatment. The database covers drug and compound names, structures, molecular formulas, cancer types used, targets, cell lines, pathways, inhibitions, references and their links. The database contains marketed drugs and clinical-stage drugs, which is a powerful instrument for new anti-tumor drugs.